References
- Gosset C, Lefaucheur C, Glotz D. New insights in antibody-mediated rejection. Curr Opin Nephrol Hypertens. 2014;23:597–604
- Klein C, DC. B. HLA and ABO sensitization and desensitization in renal transplantation. UpToDate; 2013; Available at: http://www.uptodate.com/contents/hla-and-abo-sensitization-and-desensitization-inrenal-transplantation. Accessed September 10, 2014
- Ren Q, Paramesh A, Yau CL, et al. Long-term outcome of highly sensitized African American patients transplanted with deceased donor kidneys. Transpl Int. 2011;24:259–265
- Ginevri F, Nocera A, Comoli P, et al. Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant. 2012;12: 3355–3362
- Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388–399
- Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157–1167
- Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation. 2009;87:1505–1513
- Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol. 2011;72: 849–858
- Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant. 2008;8:753–760
- Morris PJ, Mickey MR, Singal DP, Terasaki PI. Serotyping for homotransplantation. XXII. Specificity of cytotoxic antibodies developing after renal transplantation. Br Med J. 1969;22:758–759
- Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS. Humoral antibodies in renal allotransplantation in man. N Engl J Med. 1970;282:111–117
- Harmer AW, Koffman CG, Heads AJ, Vaughan RW. Sensitization to HLA antigens occurs in 95% of primary renal transplant rejections. Transplant Proc. 1995;27:666–667
- El-Awar N, Terasaki P, Lazda V, Nikaein A, Manning C, Arnold AN. Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies. Transplant Proc. 2002;34:2531–2532
- Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation. 2009;88:568–574
- Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol. 2007;18:1046–1056
- Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14: 272–283
- Mohamed MA, Muth B, Vidyasagar V, et al. Post-transplant DSA monitoring may predict antibody-mediated rejection in sensitized kidney transplant recipients. Clin Transpl. 2011:389–394
- Fehr T, Gaspert A. Antibody-mediated kidney allograft rejection: Therapeutic options and their experimental rationale. Transpl Int. 2012;25:623–632
- Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013;95:1113–1119
- Thammanichanond D, Mongkolsuk T, Rattanasiri S, et al. Significance of C1q-fixing donor-specific antibodies after kidney transplantation. Transplant Proc. 2014;46:368–371
- Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369:1215–1226